New drug cocktail aims to tame tough leukemia
NCT ID NCT03874052
First seen Apr 25, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This early-stage study tests a three-drug combination (ruxolitinib, azacitidine, and venetoclax) in adults with acute myeloid leukemia that has come back or not responded to prior therapy. The main goal is to find the safest dose and see if the combination helps control the cancer. About 51 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Ohio State University Comprehensive Cancer Center
SUSPENDEDColumbus, Ohio, 43210, United States
-
UT Southwestern/Simmons Cancer Center-Dallas
SUSPENDEDDallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.